Full-Time

Senior Scientist

Genomics in Stem Cell Sciences Group

Posted on 7/29/2024

Sana Biotechnology

Sana Biotechnology

201-500 employees

Develops engineered cell therapies for diseases

Biotechnology
Healthcare

Compensation Overview

$145k - $175kAnnually

Senior

Cambridge, MA, USA

Category
Genomics
Biology & Biotech
Requirements
  • Advanced degree in cell biology or molecular biology with 5 years of experience
  • Experience in flow cytometry, including sorting of cells based on fluorescent labels
  • Experience with library preparation for single cell genomic assays, especially the 10x Genomics Platform
  • Experience with CUT&TAG and CUT&RUN library preparation
  • Proficiency in flow cytometry analysis and quantification (ie FlowJo)
  • Experience in cell isolation from tissues
Responsibilities
  • Library preparation of epigenetics and DNA assays (CUT&TAG, CUT&RUN, WGS, WES, Amplicon-sequencing)
  • Library preparation of assays related to single cells (scRNA-seq, scATAC-seq, scMultiome-seq, CITE-seq)
  • Assure the quality, integrity, and documentation of all data collection including compliance with all relevant lab safety and biosafety regulations
  • Capture and analyze in vitro cell samples as well as in vivo samples

Sana Biotechnology develops engineered cells aimed at treating and potentially curing various diseases. Their approach focuses on addressing the root causes of diseases by repairing genes within cells or replacing damaged cells. This method allows for the creation of new types of medicines that can improve patient outcomes significantly. Sana's main clients include healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. The company invests heavily in research and development to discover new treatments, which they monetize through licensing agreements, partnerships, and direct sales. Unlike many competitors, Sana's focus on cellular and genetic medicine positions them uniquely in the biotechnology sector. Their goal is to create effective treatments that target genetic and cellular issues, ultimately enhancing patient care.

Company Stage

IPO

Total Funding

$798.6M

Headquarters

Seattle, Washington

Founded

2018

Growth & Insights
Headcount

6 month growth

4%

1 year growth

2%

2 year growth

5%
Simplify Jobs

Simplify's Take

What believers are saying

  • Fast Track designation for SC291 highlights potential in autoimmune disease treatment.
  • New Bothell facility boosts production capabilities for engineered cell therapies.
  • $189.75M PIPE offering indicates strong investor confidence and capital for R&D.

What critics are saying

  • Competition from companies like BlueRock Therapeutics may impact market share.
  • Resignation of key R&D figure, Dr. Douglas Williams, could disrupt innovation pipeline.
  • Reliance on PIPE offerings suggests potential financial instability or capital needs.

What makes Sana Biotechnology unique

  • Sana focuses on engineered cells to treat diseases at genetic and cellular levels.
  • The company targets unmet needs in autoimmune diseases with innovative hypoimmune therapies.
  • Sana's strategic partnerships and licensing deals enhance its market presence and revenue potential.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

Paid Sick Leave

Paid Holidays

Disability Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Employee Stock Purchase Plan

Commuter Benefits

INACTIVE